SlideShare a Scribd company logo
1 of 7
Download to read offline
Clinical pictures of Nickel allergy
                     Allergy to nickel: systemic effects
                             and oral immunotherapy
                                                                                                                             Type IV Hypersensitivity

                                                                                                                        Cell-mediated delayed reaction
                                                               Mario Di Gioacchino
                                                                                                           Occurs 24-72 hours after exposure to Nickel
                                           Professor of Occupational Medicine and Allergy
                                       Head of the “Immunotoxicology and Allergy” Unit
                                    “Università G. d’Annunzio” Foundation, Chieti, Italy
                                   Chair of ICOH-SC on “Allergy and Immunotoxicology”
                                    Vice president of the Italian Society of Nanotoxicology
 SC on Allergy and
Immunotoxicology



                                                                                                                                                                            Di Gioacchino




                                                    Antigen presentation                                                              Allergic contact dermatitis
                                                                                                            Initiation
                                                                                                               – CD8+ and CD4+ lymphocyte proliferation
                                                                                                            Amplification
                                                                                                               – CD8+ induced cytotoxicity
                                                                                                               – Inflammatory cytokine (IFN, TNF, IL17,) secretion
                                                                                                               – MHC-1 e MHC-2, ICAM-1 expression on epidermal cells.
                                                                                                            Damage
                                                                                                               – Eczematous lesions due to cytotoxic activity of T CD8+ cells
    Role of     APC-independent T cell presentation (full-competent                                              including infiltration of mononuclear cells in both dermis and
    activation of the T cells or mechanism involved in the maintenance of                                        epidermis, with intercellular edema between keratinocytes.
    peripheral T cell tolerance)
                                                                                  Di Gioacchino
                                                                                 Di Gioacchino                                                                              Di Gioacchino




                                                                                                       Nickel Systemic Contact Dermatitis
                                  Allergic contact dermatitis                                                  Oral challenge with Ni in Ni-ACD
Resolution
 Resolution   of   ACD    probably
  involves T cells secreting high
  levels of IL-10 (T-IL-10 ), which
  impairs the functions of dendritic
  cells, but can also directly
  modulate T cells.
 T-IL-10   cells  are   selectively
  attracted by the chemokine I-309,
  produced by activated T cells, and
  by keratinocytes


                         Modified from Cavani et al. 2001                                         Modified from Jansen Contact Dermatitis and Di Gioacchino IJIP
                                                                                 Di Gioacchino                                                                              Di Gioacchino




                                                                                                                                                                                            1
Systemic Nickel Allergy Syndrome
                              (SNAS)
             Oral challenge with Ni in Ni-ACD                          “Allergy Vaccine” International Meeting in Cyprus 2004
                                                Proceedings in “International Journal of Immunopathology and Pharmacology”                                Clinical picture of SNAS

                                                                                                                                   Nickel allergic contact dermatitis
                                                                                                                                   Systemic symptoms after ingestion of nickel rich foods:
                                                                                                                                    – Meteorism, diarrhea, vomiting, abdominal pain, GER, etc.
                                                                                                                                    – Widespread of cutaneous symptoms
                                                                                                                                    – Flare-up of previous lesions and Ni positive patch tests

                                                                                                                                 Disappearance/reduction of      symptoms after low Ni diet

                                                                                                                                 Reappearance of     symptoms after Ni oral challenge
Modified from Jansen Contact Dermatitis and Di Gioacchino IJIP
                                                                                                               Di Gioacchino                                                                         Di Gioacchino




           Dietary exposure estimates of Nickel from
                                                                                                                                        Concentration of Nickel and other elements in
                                  the UK Total Diet                                                                                             selected snack and convenience foods
          Cereals 0.17 mg/kg                                                                                                          Instant tea 7.8-12
          Poultry 0.04
          Fish 0.08                                                                                                                   Instant coffee 0.62-1.3
          Eggs 0.03
                                                                                                                                       Roasted cashews 4.1-4.7
          Green vegetables 0.11
          Other vegetables 0.09                                                                                                       Custard 0.02-0.03
          Potatoes 0.10
          Milk 0.02                                                                                                                   Lentils 1.6-2.3
          Dairy products 0.02
          Nuts 2.5                                                                                                                    Mixed nuts 0.99-5.29
                                                         Ysart G, Miller P, Crews H, Robb P, Baxter
          Fresh fruits 0.03                             M, De L'Argy C, et al. Food Additives and
                                                         Contaminants, Volume 16, Issue 9 January
                                                                                                                                       Dried peas 0.39-0.76                Archive MAFF. MAFF UK
          Oil and fats 0.03                             1999, pages 391 - 403
                                                                                                                                                                            [Last updated on 1998 Mar].
                                                                                                                                       Haricot beans 0.65-2.3
                                                                                                               Di Gioacchino                                                                         Di Gioacchino




                                                                                                                                                                  Smart GA, Sherlock JC. Food Additives
                                                                                                                                                                  Contaminants 1987;4:61-7

              A study of nickel content in Korean foods

     A green tea bag 235.57 (mg/Kg)
     A black tea bag 62.79                                                                                                                                         plant food
     Chocolate 27.87
     Crisps 12.70
                                                                                                                                                                    cereals
     Wheat flour 12.15                                                                                                                                             pulses
     Onions 0.02
     Garlic 0.016
                                                                                                                                                                    vegetables:
     Milk 0.004                                                                                                                                                      - green leavers
     Eggs 0.002
     Salt 0.0                  Han HJ, Lee BH, Park CW, Lee CH, Kang YS.
                                                                                                                                                                      - roots
                                                  Korean J Dermatol 2005;43:593-8.                                                                                    - tubers
                                                                                                              Di Gioacchino




                                                                                                                                                                                                                     2
Foods with high Ni content                                                                   Foods with high Ni content

   Oats                                Almonds                                              Crisps                         Brussels Sprouts
   Cocoa                               Hazelnuts
                                                                                              Asparagus                      Canned foods
   Chocolate                           Pears
                                                                                              Beer                           Onions
   Beans                               Soy
                                                                                              Rhubarb                        Wheat flour
   Lentils                             Spinach
                                                                                              Cabbage
   Mais                                Tomato                                                                               Mushrooms
                                                                                              Margarine
   Tea                                 Oysters                                                                              Lettuce
                                                                                              Wine
                Flyholm MA, Nielson GD, Andersen A. Zeitschrift für
                                                                                                                              Raisin
                Lebensmitteluntersuchung und -Forschung. 1984. p. 427-31
                                                                      Di Gioacchino                                                                  Di Gioacchino




          Foods with moderate Ni content                                                                         Nickel content in foods

Apricot                                                                                       Nickel linked to proteins can be stable, not
Herrings
                                                                                               all biologically available.
Broccoli
Carots                                                                                        Nickel present in the lipid portion is

Lettuce                                                                                        completely biologically available.


                                                                      Di Gioacchino                                                                  Di Gioacchino




Systemic Nickel Allergy Syndrome                                                                        SNAS: pathogenetic aspects
 There     are demonstrations that the                                               Oral Ni Challenge (5 mg) 3 pts groups: A. ACD +; SNAS -
    pathogenesis   of     SNAS     involves                                                                                       B. ACD +; SNAS +
    immunological factors unusual for a IV                                                                                        C. Healthy controls
    type immunoreactions.
                                                                                      1)   Study of nickel metabolism
                                                                                      2)   Evaluation of blood lymphocyte subpopulations
 First   hypothesis: food ingested nickel
                                                                                      3)   Lymphocyte subpopulations in the intestinal mucosa
    may act as hapten and induce an IgE
                                                                                      4)   Evaluation of “in vivo” and “in vitro” cytokine release
    medicated reaction: no scientific evidence
                                                                      Di Gioacchino                                                                  Di Gioacchino




                                                                                                                                                                     3
Changes in circulating lymphocyte
                                                              Nickel metabolism                                                                                   after Ni-challenge
Urine and serum Ni levels in controls and in ACD and SNAS women, before and 4 and 24 hours after Ni
challenge.
                                                                                                                 T cells in control and sensitized patients before and 4 and 24 h after oral nickel challenge
                                                                                                                                                                 CD4+ cell changes

                                                                                                                                         40

                                                                                                                                         30

                                                                                                                                         20

                                                                                                                                         10




                                                                                                                         % of changes
                                                                                                                                             0

                                                                                                                                        -10

                                                                                                                                        -20

                                                                                                                                        -30

                                                                                                                                        -40

                                                                                                                                        -50
                                                                                                                                          basal                         test 2                          test 3

                                                                                                                                                      controls         group A       group B
                                    M. Di Gioacchino et al: Arbeitstagung Mengen und Spurenelemente. 1995
                                                                                                Di Gioacchino    M. Di Gioacchino, et al Contact Dermatitis 2000                                                 Di Gioacchino




                            Changes in circulating lymphocyte                                                                                     Changes in circulating lymphocyte
                                            after Ni-challenge                                                                                                    after Ni-challenge
                                                                                                                 T cells in control and sensitized patients before and 4 and 24 h after oral nickel challenge
T cells in control and sensitized patients before and 4 and 24 h after oral nickel challenge
                                                                                                                                                                 CD8+ cell changes
                                           CD4+CD45RO+ cell changes

                  30                                                                                                                    40

                                                                                                                                        30
                  20
                                                                                                                                        20

                  10                                                                                                                    10
   % of changes




                                                                                                                  % of changes




                                                                                                                                        0
                   0
                                                                                                                                    -10
                  -10
                                                                                                                                    -20

                  -20                                                                                                               -30

                                                                                                                                    -40
                  -30
                                                                                                                                    -50
                  -40                                                                                                               -60
                    basal                           test 2                             test 3                                         basal                           test 2                           test 3

                                controls            group A           group B                                                                         controls         group A       group B


  M. Di Gioacchino, et al. Contact Dermatitis 2000                                              Di Gioacchino    M. Di Gioacchino, et al Contact Dermatitis 2000                                                 Di Gioacchino




 CD4 in intestinal epithelium after Ni-challenge                                                                 CD8 in intestinal epithelium after Ni-challenge




M. Di Gioacchino, et al Lymphocyte subset changes in blood and gastrointestinal mucosa after                    M. Di Gioacchino, et al Lymphocyte subset changes in blood and gastrointestinal mucosa after
oral nickel challenge, in nickel sensitized women. Contact Dermatitis 43; 2000                  Di Gioacchino   oral nickel challenge, in nickel sensitized women. Contact Dermatitis 43; 2000                   Di Gioacchino




                                                                                                                                                                                                                                 4
IL-5 and Nickel Allergy                                                                                        IL-5 and Nickel Allergy
                                                                                                                   IL5 in control and sensitized patients before and after oral nickel exposure
IL5 % changes 24 h after oral nickel challenge in control subjects and in patients
with Ni-DAC and Systemic Nickel Allergy Syndrome.
                                                                   *
  60%

  40%

  20%                                                                                  IL-2
                                                                                       IL-5
   0%

 -20%

 -40%
                controls                   DAC                   SNAS
                                                                              * (p<0.01)
 Modified from                                                                                                                                                        CS Jensen, et al Contact Dermatitis 2004
 M. Di Gioacchino et al: Life Sciences 64:1485-1491; 1999                                   Di Gioacchino   CS Jensen, et al Contact Dermatitis 2004                                                    Di Gioacchino




                                                                                                                    Is it possible to modulate cytokines
                In vitro Ni induced cytokine release                                                                           release in SNAS patients?
                                                                  p=0,001

                                                                                                               Oral nickel treatment in SNAS patients (open
                                                                                                                study) comparing:
                  p=ns
                                                                                                                – Low Ni diet + oral nickel (group 1)
                                  p=0,01
                                                                                                                – Low Ni diet alone (group 2)
                                                                                     p=ns
                                                                                                               End points:
                                                  p=0,01                                                        – cytokine release from ex-vivo Ni-stimulated cells
                                                                                                                  comparison pre v/s post treatment
                                                                                                                – clinical outcome (VAS, rescue medications)
Di Gioacchino M, et al                                                                      Di Gioacchino   Minelli et al IJIP 2010                                                                     Di Gioacchino




                                                                                                                     Changes (%) in Th1,Th2, Treg cytokine release
                                                 Treatment schedule                                                                 pre- post treatment (diet alone)

       After an increasing phase, 1.5 µg Ni/week was
        orally administered for a year.

       Low Nickel diet – Brama-Ni (author M. Braga)
        (www.lofarma.it/static/upl/Al/Allergianichel_COP_bassa.pdf)


       Gradual reintroduction of Ni containing foods
        from the seventh month of treatment

Minelli et al IJIP 2010                                                                     Di Gioacchino   Minelli et al IJIP 2010                                                                    Di Gioacchino




                                                                                                                                                                                                                        5
Changes (%) in Th1,Th2, Treg cytokine release
                                pre- post Ni treatment                                                                       Clinical outcome
                                                                                                 VAS significantly better in group 1 respect to
                                                                                                  group 2 at the end of treatment;
                 p=0,05
                 p=0,07
                                p=0,05
                               p=0,006
                                             p=0,05
                                             p=0,05
                                                          p=0,005
                                                          p=0,002                                The number of patients necessitating rescue
                                                                        p=0,004
                                                                       p=0,004                    medications significantly lower in group 1
                                                                                                  respect to group 2.


                                                                                                  The open study does not allow to definitely
                                                                                                  establish the efficacy of a treatment
Minelli et al IJIP 2010                                                   Di Gioacchino    Minelli et al IJIP 2010                              Di Gioacchino




          Double blind placebo controlled study on the                                                                  Outline of the study
           efficacy and tolerability of the desensitizing
         therapy with nickel in patients suffering from                                     This was a 60 week, prospective, randomized, double
                                                                                            blind, placebo controlled phase III trial, with four
            Systemic Nickel Allergy Syndrome (SNAS)                                         parallel groups.

                                                                                            Inclusion criteria were:
                          Participating researchers:                                        1) Presence of Ni-ACD (confirmed by patch test);

                          M. Di Gioacchino (coordinator - Chieti), O. De Pità               2) History of gastrointestinal and/or cutaneous
                          (Roma), V. Di Rienzo (Latina), M. Minelli (Lecce), V.                symptoms of SNAS;
                          Patella (Salerno), L. Ricciardi (Messina), D. Schiavino
                                                                                            3) At least 70% clinical improvement after 1 month low
                          (Roma), S. Voltolini (Genova).
                                                                                               nickel diet;
                                                                                            4) Positivity of the Ni oral challenge.
                                                                                                                                                Di Gioacchino




                                          Outline of the study                                                                             Results
4 Groups                                                                                     Results of the study demonstrated the effectiveness
–   Group 1: Maintenance dose 1.5 µg/week                                                    of the treatment.
–   Group 2: Maintenance dose 0.3 µg/week
–   Group 3: Maintenance dose 30 ng/week
–   Group 4: Placebo                                                                         The work are under review in a scientific journal, the
                                                                                             data will be made public as soon as the manuscript
        End point: disappearance/reduction of symptoms                                      will be published.
         evaluated as difference in post/pre
             –    VAS
             –    Gastrointestinal and cutaneous symptoms
             –    Oral challenge with Nickel
             –    Drug consumption
                                                                           Di Gioacchino                                                        Di Gioacchino




                                                                                                                                                                6
Conclusions
   SNAS has a definite clinical pattern and is characterized by
                                                                            Thankyou for your attention
    specific immunologic features respect to Ni-ACD

   Oral administration of Ni induces immunological changes
    (essentially reduction of Ni-induced inflammatory cytokine
    and increase in Ni induced regulatory cytokines) and clinical
    improvement.
                                                                                m.digioacchino@unich.it


                                                            Di Gioacchino




                                                                                                          7

More Related Content

What's hot (20)

Resin Infiltration Technique
Resin Infiltration TechniqueResin Infiltration Technique
Resin Infiltration Technique
 
Cephalometrics
Cephalometrics Cephalometrics
Cephalometrics
 
Occlusal assesment/ dental courses
Occlusal assesment/ dental coursesOcclusal assesment/ dental courses
Occlusal assesment/ dental courses
 
Func tional matrix theory
Func  tional matrix theoryFunc  tional matrix theory
Func tional matrix theory
 
Refractory periodontitis
Refractory periodontitisRefractory periodontitis
Refractory periodontitis
 
Modified widman flap
Modified widman flapModified widman flap
Modified widman flap
 
Theories of growth
Theories of growth Theories of growth
Theories of growth
 
Osteoradionecrosis
OsteoradionecrosisOsteoradionecrosis
Osteoradionecrosis
 
Gingival surgical techniques/Gingivectomy
Gingival surgical techniques/GingivectomyGingival surgical techniques/Gingivectomy
Gingival surgical techniques/Gingivectomy
 
Neutral zone in complete dentures
Neutral zone in complete denturesNeutral zone in complete dentures
Neutral zone in complete dentures
 
Peri implantitis treatment protocol
Peri implantitis treatment protocolPeri implantitis treatment protocol
Peri implantitis treatment protocol
 
MTA
MTAMTA
MTA
 
Dental mobility
Dental mobilityDental mobility
Dental mobility
 
Tmj disorders
Tmj disordersTmj disorders
Tmj disorders
 
bite planes
bite planesbite planes
bite planes
 
Myofunctional appliances
Myofunctional appliancesMyofunctional appliances
Myofunctional appliances
 
Molar incisor hypomineralization
Molar incisor  hypomineralization Molar incisor  hypomineralization
Molar incisor hypomineralization
 
Radio CBCT present
Radio CBCT presentRadio CBCT present
Radio CBCT present
 
Normal microflora
Normal microflora Normal microflora
Normal microflora
 
stress trajectories of force
stress trajectories of forcestress trajectories of force
stress trajectories of force
 

More from Juan Carlos Ivancevich

Sesión Académica del CRAIC "Biológicos en la era de las enfermedades alérgicas"
Sesión Académica del CRAIC "Biológicos en la era de las enfermedades alérgicas"Sesión Académica del CRAIC "Biológicos en la era de las enfermedades alérgicas"
Sesión Académica del CRAIC "Biológicos en la era de las enfermedades alérgicas"Juan Carlos Ivancevich
 
Vacunas COVID: Lo Que Todo Alergista Debe Saber
Vacunas COVID: Lo Que Todo Alergista Debe SaberVacunas COVID: Lo Que Todo Alergista Debe Saber
Vacunas COVID: Lo Que Todo Alergista Debe SaberJuan Carlos Ivancevich
 
Sesión Clínica del CRAIC "Síndrome de alergia oral 2021"
Sesión Clínica del CRAIC "Síndrome de alergia oral 2021"Sesión Clínica del CRAIC "Síndrome de alergia oral 2021"
Sesión Clínica del CRAIC "Síndrome de alergia oral 2021"Juan Carlos Ivancevich
 
Sesión Académica del CRAIC "GUIMIT 2019"
Sesión Académica del CRAIC "GUIMIT 2019"Sesión Académica del CRAIC "GUIMIT 2019"
Sesión Académica del CRAIC "GUIMIT 2019"Juan Carlos Ivancevich
 
Sesión de Inmunología del CRAIC "Abordaje de las inmunodeficiencias primarias".
Sesión de Inmunología del CRAIC "Abordaje de las inmunodeficiencias primarias".Sesión de Inmunología del CRAIC "Abordaje de las inmunodeficiencias primarias".
Sesión de Inmunología del CRAIC "Abordaje de las inmunodeficiencias primarias".Juan Carlos Ivancevich
 
Sesión Académica del CRAIC "Dermatitis atópica"
Sesión Académica del CRAIC "Dermatitis atópica"Sesión Académica del CRAIC "Dermatitis atópica"
Sesión Académica del CRAIC "Dermatitis atópica"Juan Carlos Ivancevich
 
Sesión Clínica del CRAIC "Conjuntivitis alérgica".
Sesión Clínica del CRAIC "Conjuntivitis alérgica".Sesión Clínica del CRAIC "Conjuntivitis alérgica".
Sesión Clínica del CRAIC "Conjuntivitis alérgica".Juan Carlos Ivancevich
 
Sesión Académica del CRAIC "Guía GEMA"
Sesión Académica del CRAIC "Guía GEMA"Sesión Académica del CRAIC "Guía GEMA"
Sesión Académica del CRAIC "Guía GEMA"Juan Carlos Ivancevich
 
Sesión Académica del CRAIC "Guía GINA 2020"
Sesión Académica del CRAIC "Guía GINA 2020"Sesión Académica del CRAIC "Guía GINA 2020"
Sesión Académica del CRAIC "Guía GINA 2020"Juan Carlos Ivancevich
 
Sesión Clínica del CRAIC "Abordaje clínico y terapéutico de pacientes con rin...
Sesión Clínica del CRAIC "Abordaje clínico y terapéutico de pacientes con rin...Sesión Clínica del CRAIC "Abordaje clínico y terapéutico de pacientes con rin...
Sesión Clínica del CRAIC "Abordaje clínico y terapéutico de pacientes con rin...Juan Carlos Ivancevich
 
Sesión Académica del CRAIC "Rinitis Alérgica: Guías ARIA-MACVIA".
Sesión Académica del CRAIC "Rinitis Alérgica: Guías ARIA-MACVIA".Sesión Académica del CRAIC "Rinitis Alérgica: Guías ARIA-MACVIA".
Sesión Académica del CRAIC "Rinitis Alérgica: Guías ARIA-MACVIA".Juan Carlos Ivancevich
 
Sesión de Inmunología del CRAIC "Trastornos de la inmunidad innata".
Sesión de Inmunología del CRAIC "Trastornos de la inmunidad innata".Sesión de Inmunología del CRAIC "Trastornos de la inmunidad innata".
Sesión de Inmunología del CRAIC "Trastornos de la inmunidad innata".Juan Carlos Ivancevich
 
Sesión Académica del CRAIC "Alergia y COVID"
Sesión Académica del CRAIC "Alergia y COVID"Sesión Académica del CRAIC "Alergia y COVID"
Sesión Académica del CRAIC "Alergia y COVID"Juan Carlos Ivancevich
 
Sesión Clínica del CRAIC: "Alergias, inmunocompromiso y COVID-19"
Sesión Clínica del CRAIC: "Alergias, inmunocompromiso y COVID-19"Sesión Clínica del CRAIC: "Alergias, inmunocompromiso y COVID-19"
Sesión Clínica del CRAIC: "Alergias, inmunocompromiso y COVID-19"Juan Carlos Ivancevich
 
Vacunas contra Covid - Actualización de lo que el alergólogo debe conocer. Pr...
Vacunas contra Covid - Actualización de lo que el alergólogo debe conocer. Pr...Vacunas contra Covid - Actualización de lo que el alergólogo debe conocer. Pr...
Vacunas contra Covid - Actualización de lo que el alergólogo debe conocer. Pr...Juan Carlos Ivancevich
 
Sesión Académica del CRAIC "Fibromialgia y espondiloartropatías"
Sesión Académica del CRAIC "Fibromialgia y espondiloartropatías"Sesión Académica del CRAIC "Fibromialgia y espondiloartropatías"
Sesión Académica del CRAIC "Fibromialgia y espondiloartropatías"Juan Carlos Ivancevich
 
Sesión Clínica del CRAIC "Prurito crónico"
Sesión Clínica del CRAIC "Prurito crónico"Sesión Clínica del CRAIC "Prurito crónico"
Sesión Clínica del CRAIC "Prurito crónico"Juan Carlos Ivancevich
 
Respuesta inmunológica hacia SARS-CoV-2 Prof. Dr. Ortega Martell
Respuesta inmunológica hacia SARS-CoV-2 Prof. Dr. Ortega MartellRespuesta inmunológica hacia SARS-CoV-2 Prof. Dr. Ortega Martell
Respuesta inmunológica hacia SARS-CoV-2 Prof. Dr. Ortega MartellJuan Carlos Ivancevich
 
WAO "Special Session - in View of WISC 2020: Allergy and COVID"
WAO "Special Session - in View of WISC 2020: Allergy and COVID"WAO "Special Session - in View of WISC 2020: Allergy and COVID"
WAO "Special Session - in View of WISC 2020: Allergy and COVID"Juan Carlos Ivancevich
 

More from Juan Carlos Ivancevich (20)

Sesión Académica del CRAIC "Biológicos en la era de las enfermedades alérgicas"
Sesión Académica del CRAIC "Biológicos en la era de las enfermedades alérgicas"Sesión Académica del CRAIC "Biológicos en la era de las enfermedades alérgicas"
Sesión Académica del CRAIC "Biológicos en la era de las enfermedades alérgicas"
 
Vacunas COVID: Lo Que Todo Alergista Debe Saber
Vacunas COVID: Lo Que Todo Alergista Debe SaberVacunas COVID: Lo Que Todo Alergista Debe Saber
Vacunas COVID: Lo Que Todo Alergista Debe Saber
 
Sesión Clínica del CRAIC "Síndrome de alergia oral 2021"
Sesión Clínica del CRAIC "Síndrome de alergia oral 2021"Sesión Clínica del CRAIC "Síndrome de alergia oral 2021"
Sesión Clínica del CRAIC "Síndrome de alergia oral 2021"
 
Sesión Académica del CRAIC "GUIMIT 2019"
Sesión Académica del CRAIC "GUIMIT 2019"Sesión Académica del CRAIC "GUIMIT 2019"
Sesión Académica del CRAIC "GUIMIT 2019"
 
Sesión de Inmunología del CRAIC "Abordaje de las inmunodeficiencias primarias".
Sesión de Inmunología del CRAIC "Abordaje de las inmunodeficiencias primarias".Sesión de Inmunología del CRAIC "Abordaje de las inmunodeficiencias primarias".
Sesión de Inmunología del CRAIC "Abordaje de las inmunodeficiencias primarias".
 
Sesión Académica del CRAIC "Dermatitis atópica"
Sesión Académica del CRAIC "Dermatitis atópica"Sesión Académica del CRAIC "Dermatitis atópica"
Sesión Académica del CRAIC "Dermatitis atópica"
 
Sesión Clínica del CRAIC "Conjuntivitis alérgica".
Sesión Clínica del CRAIC "Conjuntivitis alérgica".Sesión Clínica del CRAIC "Conjuntivitis alérgica".
Sesión Clínica del CRAIC "Conjuntivitis alérgica".
 
Sesión Académica del CRAIC "Guía GEMA"
Sesión Académica del CRAIC "Guía GEMA"Sesión Académica del CRAIC "Guía GEMA"
Sesión Académica del CRAIC "Guía GEMA"
 
Sesión Académica del CRAIC "Guía GINA 2020"
Sesión Académica del CRAIC "Guía GINA 2020"Sesión Académica del CRAIC "Guía GINA 2020"
Sesión Académica del CRAIC "Guía GINA 2020"
 
Sesión Clínica del CRAIC "Abordaje clínico y terapéutico de pacientes con rin...
Sesión Clínica del CRAIC "Abordaje clínico y terapéutico de pacientes con rin...Sesión Clínica del CRAIC "Abordaje clínico y terapéutico de pacientes con rin...
Sesión Clínica del CRAIC "Abordaje clínico y terapéutico de pacientes con rin...
 
Sesión Académica del CRAIC "Rinitis Alérgica: Guías ARIA-MACVIA".
Sesión Académica del CRAIC "Rinitis Alérgica: Guías ARIA-MACVIA".Sesión Académica del CRAIC "Rinitis Alérgica: Guías ARIA-MACVIA".
Sesión Académica del CRAIC "Rinitis Alérgica: Guías ARIA-MACVIA".
 
Sesión de Inmunología del CRAIC "Trastornos de la inmunidad innata".
Sesión de Inmunología del CRAIC "Trastornos de la inmunidad innata".Sesión de Inmunología del CRAIC "Trastornos de la inmunidad innata".
Sesión de Inmunología del CRAIC "Trastornos de la inmunidad innata".
 
Sesión Académica del CRAIC "Alergia y COVID"
Sesión Académica del CRAIC "Alergia y COVID"Sesión Académica del CRAIC "Alergia y COVID"
Sesión Académica del CRAIC "Alergia y COVID"
 
Sesión Clínica del CRAIC: "Alergias, inmunocompromiso y COVID-19"
Sesión Clínica del CRAIC: "Alergias, inmunocompromiso y COVID-19"Sesión Clínica del CRAIC: "Alergias, inmunocompromiso y COVID-19"
Sesión Clínica del CRAIC: "Alergias, inmunocompromiso y COVID-19"
 
Vacunas contra Covid - Actualización de lo que el alergólogo debe conocer. Pr...
Vacunas contra Covid - Actualización de lo que el alergólogo debe conocer. Pr...Vacunas contra Covid - Actualización de lo que el alergólogo debe conocer. Pr...
Vacunas contra Covid - Actualización de lo que el alergólogo debe conocer. Pr...
 
Sesión Académica del CRAIC "Fibromialgia y espondiloartropatías"
Sesión Académica del CRAIC "Fibromialgia y espondiloartropatías"Sesión Académica del CRAIC "Fibromialgia y espondiloartropatías"
Sesión Académica del CRAIC "Fibromialgia y espondiloartropatías"
 
Sesión Clínica del CRAIC "Prurito crónico"
Sesión Clínica del CRAIC "Prurito crónico"Sesión Clínica del CRAIC "Prurito crónico"
Sesión Clínica del CRAIC "Prurito crónico"
 
Asma y obesidad 2021
Asma y obesidad 2021Asma y obesidad 2021
Asma y obesidad 2021
 
Respuesta inmunológica hacia SARS-CoV-2 Prof. Dr. Ortega Martell
Respuesta inmunológica hacia SARS-CoV-2 Prof. Dr. Ortega MartellRespuesta inmunológica hacia SARS-CoV-2 Prof. Dr. Ortega Martell
Respuesta inmunológica hacia SARS-CoV-2 Prof. Dr. Ortega Martell
 
WAO "Special Session - in View of WISC 2020: Allergy and COVID"
WAO "Special Session - in View of WISC 2020: Allergy and COVID"WAO "Special Session - in View of WISC 2020: Allergy and COVID"
WAO "Special Session - in View of WISC 2020: Allergy and COVID"
 

Recently uploaded

NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019Akash Agnihotri
 
Dermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdfDermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdfniloofarbarzegari76
 
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...Health Kinesiology Natural Bioenergetics
 
Varicose Veins Treatment Aftercare Tips by Gokuldas Hospital
Varicose Veins Treatment Aftercare Tips by Gokuldas HospitalVaricose Veins Treatment Aftercare Tips by Gokuldas Hospital
Varicose Veins Treatment Aftercare Tips by Gokuldas HospitalGokuldas Hospital
 
Sell pmk powder cas 28578-16-7 from pmk supplier Telegram +85297504341
Sell pmk powder cas 28578-16-7 from pmk supplier Telegram +85297504341Sell pmk powder cas 28578-16-7 from pmk supplier Telegram +85297504341
Sell pmk powder cas 28578-16-7 from pmk supplier Telegram +85297504341Sherrylee83
 
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...Ayman Seddik
 
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdfSEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdfSachin Sharma
 
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالةGallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالةMohamad محمد Al-Gailani الكيلاني
 
Signs It’s Time for Physiotherapy Sessions Prioritizing Wellness
Signs It’s Time for Physiotherapy Sessions Prioritizing WellnessSigns It’s Time for Physiotherapy Sessions Prioritizing Wellness
Signs It’s Time for Physiotherapy Sessions Prioritizing WellnessGokuldas Hospital
 
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depthsUnveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depthsYash Garg
 
Tips and tricks to pass the cardiovascular station for PACES exam
Tips and tricks to pass the cardiovascular station for PACES examTips and tricks to pass the cardiovascular station for PACES exam
Tips and tricks to pass the cardiovascular station for PACES examJunhao Koh
 
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerSherrylee83
 
Denture base resins materials and its mechanism of action
Denture base resins materials and its mechanism of actionDenture base resins materials and its mechanism of action
Denture base resins materials and its mechanism of actionDr.shiva sai vemula
 
Let's Talk About It: Ovarian Cancer (The Emotional Toll of Treatment Decision...
Let's Talk About It: Ovarian Cancer (The Emotional Toll of Treatment Decision...Let's Talk About It: Ovarian Cancer (The Emotional Toll of Treatment Decision...
Let's Talk About It: Ovarian Cancer (The Emotional Toll of Treatment Decision...bkling
 
Overview on the Automatic pill identifier
Overview on the Automatic pill identifierOverview on the Automatic pill identifier
Overview on the Automatic pill identifierNidhi Joshi
 
ESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failureESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failuremahiavy26
 
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATROROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATROKanhu Charan
 
The Clean Living Project Episode 24 - Subconscious
The Clean Living Project Episode 24 - SubconsciousThe Clean Living Project Episode 24 - Subconscious
The Clean Living Project Episode 24 - SubconsciousThe Clean Living Project
 
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose AcademicsConnective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose AcademicsMedicoseAcademics
 
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose AcademicsCytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose AcademicsMedicoseAcademics
 

Recently uploaded (20)

NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019
 
Dermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdfDermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdf
 
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
 
Varicose Veins Treatment Aftercare Tips by Gokuldas Hospital
Varicose Veins Treatment Aftercare Tips by Gokuldas HospitalVaricose Veins Treatment Aftercare Tips by Gokuldas Hospital
Varicose Veins Treatment Aftercare Tips by Gokuldas Hospital
 
Sell pmk powder cas 28578-16-7 from pmk supplier Telegram +85297504341
Sell pmk powder cas 28578-16-7 from pmk supplier Telegram +85297504341Sell pmk powder cas 28578-16-7 from pmk supplier Telegram +85297504341
Sell pmk powder cas 28578-16-7 from pmk supplier Telegram +85297504341
 
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
 
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdfSEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
 
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالةGallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
 
Signs It’s Time for Physiotherapy Sessions Prioritizing Wellness
Signs It’s Time for Physiotherapy Sessions Prioritizing WellnessSigns It’s Time for Physiotherapy Sessions Prioritizing Wellness
Signs It’s Time for Physiotherapy Sessions Prioritizing Wellness
 
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depthsUnveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
 
Tips and tricks to pass the cardiovascular station for PACES exam
Tips and tricks to pass the cardiovascular station for PACES examTips and tricks to pass the cardiovascular station for PACES exam
Tips and tricks to pass the cardiovascular station for PACES exam
 
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
 
Denture base resins materials and its mechanism of action
Denture base resins materials and its mechanism of actionDenture base resins materials and its mechanism of action
Denture base resins materials and its mechanism of action
 
Let's Talk About It: Ovarian Cancer (The Emotional Toll of Treatment Decision...
Let's Talk About It: Ovarian Cancer (The Emotional Toll of Treatment Decision...Let's Talk About It: Ovarian Cancer (The Emotional Toll of Treatment Decision...
Let's Talk About It: Ovarian Cancer (The Emotional Toll of Treatment Decision...
 
Overview on the Automatic pill identifier
Overview on the Automatic pill identifierOverview on the Automatic pill identifier
Overview on the Automatic pill identifier
 
ESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failureESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failure
 
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATROROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
 
The Clean Living Project Episode 24 - Subconscious
The Clean Living Project Episode 24 - SubconsciousThe Clean Living Project Episode 24 - Subconscious
The Clean Living Project Episode 24 - Subconscious
 
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose AcademicsConnective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
Connective Tissue II - Dr Muhammad Ali Rabbani - Medicose Academics
 
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose AcademicsCytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
Cytoskeleton and Cell Inclusions - Dr Muhammad Ali Rabbani - Medicose Academics
 

Allergy to nickel: Systemic effects and oral immunotherapy

  • 1. Clinical pictures of Nickel allergy Allergy to nickel: systemic effects and oral immunotherapy Type IV Hypersensitivity Cell-mediated delayed reaction Mario Di Gioacchino Occurs 24-72 hours after exposure to Nickel Professor of Occupational Medicine and Allergy Head of the “Immunotoxicology and Allergy” Unit “Università G. d’Annunzio” Foundation, Chieti, Italy Chair of ICOH-SC on “Allergy and Immunotoxicology” Vice president of the Italian Society of Nanotoxicology SC on Allergy and Immunotoxicology Di Gioacchino Antigen presentation Allergic contact dermatitis  Initiation – CD8+ and CD4+ lymphocyte proliferation  Amplification – CD8+ induced cytotoxicity – Inflammatory cytokine (IFN, TNF, IL17,) secretion – MHC-1 e MHC-2, ICAM-1 expression on epidermal cells.  Damage – Eczematous lesions due to cytotoxic activity of T CD8+ cells Role of APC-independent T cell presentation (full-competent including infiltration of mononuclear cells in both dermis and activation of the T cells or mechanism involved in the maintenance of epidermis, with intercellular edema between keratinocytes. peripheral T cell tolerance) Di Gioacchino Di Gioacchino Di Gioacchino Nickel Systemic Contact Dermatitis Allergic contact dermatitis Oral challenge with Ni in Ni-ACD Resolution  Resolution of ACD probably involves T cells secreting high levels of IL-10 (T-IL-10 ), which impairs the functions of dendritic cells, but can also directly modulate T cells.  T-IL-10 cells are selectively attracted by the chemokine I-309, produced by activated T cells, and by keratinocytes Modified from Cavani et al. 2001 Modified from Jansen Contact Dermatitis and Di Gioacchino IJIP Di Gioacchino Di Gioacchino 1
  • 2. Systemic Nickel Allergy Syndrome (SNAS) Oral challenge with Ni in Ni-ACD “Allergy Vaccine” International Meeting in Cyprus 2004 Proceedings in “International Journal of Immunopathology and Pharmacology” Clinical picture of SNAS  Nickel allergic contact dermatitis  Systemic symptoms after ingestion of nickel rich foods: – Meteorism, diarrhea, vomiting, abdominal pain, GER, etc. – Widespread of cutaneous symptoms – Flare-up of previous lesions and Ni positive patch tests  Disappearance/reduction of symptoms after low Ni diet  Reappearance of symptoms after Ni oral challenge Modified from Jansen Contact Dermatitis and Di Gioacchino IJIP Di Gioacchino Di Gioacchino Dietary exposure estimates of Nickel from Concentration of Nickel and other elements in the UK Total Diet selected snack and convenience foods  Cereals 0.17 mg/kg  Instant tea 7.8-12  Poultry 0.04  Fish 0.08  Instant coffee 0.62-1.3  Eggs 0.03  Roasted cashews 4.1-4.7  Green vegetables 0.11  Other vegetables 0.09  Custard 0.02-0.03  Potatoes 0.10  Milk 0.02  Lentils 1.6-2.3  Dairy products 0.02  Nuts 2.5  Mixed nuts 0.99-5.29 Ysart G, Miller P, Crews H, Robb P, Baxter  Fresh fruits 0.03 M, De L'Argy C, et al. Food Additives and Contaminants, Volume 16, Issue 9 January  Dried peas 0.39-0.76 Archive MAFF. MAFF UK  Oil and fats 0.03 1999, pages 391 - 403 [Last updated on 1998 Mar].  Haricot beans 0.65-2.3 Di Gioacchino Di Gioacchino Smart GA, Sherlock JC. Food Additives Contaminants 1987;4:61-7 A study of nickel content in Korean foods  A green tea bag 235.57 (mg/Kg)  A black tea bag 62.79 plant food  Chocolate 27.87  Crisps 12.70 cereals  Wheat flour 12.15 pulses  Onions 0.02  Garlic 0.016 vegetables:  Milk 0.004 - green leavers  Eggs 0.002  Salt 0.0 Han HJ, Lee BH, Park CW, Lee CH, Kang YS. - roots Korean J Dermatol 2005;43:593-8. - tubers Di Gioacchino 2
  • 3. Foods with high Ni content Foods with high Ni content  Oats  Almonds  Crisps  Brussels Sprouts  Cocoa  Hazelnuts  Asparagus  Canned foods  Chocolate  Pears  Beer  Onions  Beans  Soy  Rhubarb  Wheat flour  Lentils  Spinach  Cabbage  Mais  Tomato  Mushrooms  Margarine  Tea  Oysters  Lettuce  Wine Flyholm MA, Nielson GD, Andersen A. Zeitschrift für  Raisin Lebensmitteluntersuchung und -Forschung. 1984. p. 427-31 Di Gioacchino Di Gioacchino Foods with moderate Ni content Nickel content in foods Apricot  Nickel linked to proteins can be stable, not Herrings all biologically available. Broccoli Carots  Nickel present in the lipid portion is Lettuce completely biologically available. Di Gioacchino Di Gioacchino Systemic Nickel Allergy Syndrome SNAS: pathogenetic aspects  There are demonstrations that the Oral Ni Challenge (5 mg) 3 pts groups: A. ACD +; SNAS - pathogenesis of SNAS involves B. ACD +; SNAS + immunological factors unusual for a IV C. Healthy controls type immunoreactions. 1) Study of nickel metabolism 2) Evaluation of blood lymphocyte subpopulations  First hypothesis: food ingested nickel 3) Lymphocyte subpopulations in the intestinal mucosa may act as hapten and induce an IgE 4) Evaluation of “in vivo” and “in vitro” cytokine release medicated reaction: no scientific evidence Di Gioacchino Di Gioacchino 3
  • 4. Changes in circulating lymphocyte Nickel metabolism after Ni-challenge Urine and serum Ni levels in controls and in ACD and SNAS women, before and 4 and 24 hours after Ni challenge. T cells in control and sensitized patients before and 4 and 24 h after oral nickel challenge CD4+ cell changes 40 30 20 10 % of changes 0 -10 -20 -30 -40 -50 basal test 2 test 3 controls group A group B M. Di Gioacchino et al: Arbeitstagung Mengen und Spurenelemente. 1995 Di Gioacchino M. Di Gioacchino, et al Contact Dermatitis 2000 Di Gioacchino Changes in circulating lymphocyte Changes in circulating lymphocyte after Ni-challenge after Ni-challenge T cells in control and sensitized patients before and 4 and 24 h after oral nickel challenge T cells in control and sensitized patients before and 4 and 24 h after oral nickel challenge CD8+ cell changes CD4+CD45RO+ cell changes 30 40 30 20 20 10 10 % of changes % of changes 0 0 -10 -10 -20 -20 -30 -40 -30 -50 -40 -60 basal test 2 test 3 basal test 2 test 3 controls group A group B controls group A group B M. Di Gioacchino, et al. Contact Dermatitis 2000 Di Gioacchino M. Di Gioacchino, et al Contact Dermatitis 2000 Di Gioacchino CD4 in intestinal epithelium after Ni-challenge CD8 in intestinal epithelium after Ni-challenge M. Di Gioacchino, et al Lymphocyte subset changes in blood and gastrointestinal mucosa after M. Di Gioacchino, et al Lymphocyte subset changes in blood and gastrointestinal mucosa after oral nickel challenge, in nickel sensitized women. Contact Dermatitis 43; 2000 Di Gioacchino oral nickel challenge, in nickel sensitized women. Contact Dermatitis 43; 2000 Di Gioacchino 4
  • 5. IL-5 and Nickel Allergy IL-5 and Nickel Allergy IL5 in control and sensitized patients before and after oral nickel exposure IL5 % changes 24 h after oral nickel challenge in control subjects and in patients with Ni-DAC and Systemic Nickel Allergy Syndrome. * 60% 40% 20% IL-2 IL-5 0% -20% -40% controls DAC SNAS * (p<0.01) Modified from CS Jensen, et al Contact Dermatitis 2004 M. Di Gioacchino et al: Life Sciences 64:1485-1491; 1999 Di Gioacchino CS Jensen, et al Contact Dermatitis 2004 Di Gioacchino Is it possible to modulate cytokines In vitro Ni induced cytokine release release in SNAS patients? p=0,001  Oral nickel treatment in SNAS patients (open study) comparing: p=ns – Low Ni diet + oral nickel (group 1) p=0,01 – Low Ni diet alone (group 2) p=ns  End points: p=0,01 – cytokine release from ex-vivo Ni-stimulated cells comparison pre v/s post treatment – clinical outcome (VAS, rescue medications) Di Gioacchino M, et al Di Gioacchino Minelli et al IJIP 2010 Di Gioacchino Changes (%) in Th1,Th2, Treg cytokine release Treatment schedule pre- post treatment (diet alone)  After an increasing phase, 1.5 µg Ni/week was orally administered for a year.  Low Nickel diet – Brama-Ni (author M. Braga) (www.lofarma.it/static/upl/Al/Allergianichel_COP_bassa.pdf)  Gradual reintroduction of Ni containing foods from the seventh month of treatment Minelli et al IJIP 2010 Di Gioacchino Minelli et al IJIP 2010 Di Gioacchino 5
  • 6. Changes (%) in Th1,Th2, Treg cytokine release pre- post Ni treatment Clinical outcome  VAS significantly better in group 1 respect to group 2 at the end of treatment; p=0,05 p=0,07 p=0,05 p=0,006 p=0,05 p=0,05 p=0,005 p=0,002  The number of patients necessitating rescue p=0,004 p=0,004 medications significantly lower in group 1 respect to group 2. The open study does not allow to definitely establish the efficacy of a treatment Minelli et al IJIP 2010 Di Gioacchino Minelli et al IJIP 2010 Di Gioacchino Double blind placebo controlled study on the Outline of the study efficacy and tolerability of the desensitizing therapy with nickel in patients suffering from This was a 60 week, prospective, randomized, double blind, placebo controlled phase III trial, with four Systemic Nickel Allergy Syndrome (SNAS) parallel groups. Inclusion criteria were: Participating researchers: 1) Presence of Ni-ACD (confirmed by patch test); M. Di Gioacchino (coordinator - Chieti), O. De Pità 2) History of gastrointestinal and/or cutaneous (Roma), V. Di Rienzo (Latina), M. Minelli (Lecce), V. symptoms of SNAS; Patella (Salerno), L. Ricciardi (Messina), D. Schiavino 3) At least 70% clinical improvement after 1 month low (Roma), S. Voltolini (Genova). nickel diet; 4) Positivity of the Ni oral challenge. Di Gioacchino Outline of the study Results 4 Groups Results of the study demonstrated the effectiveness – Group 1: Maintenance dose 1.5 µg/week of the treatment. – Group 2: Maintenance dose 0.3 µg/week – Group 3: Maintenance dose 30 ng/week – Group 4: Placebo The work are under review in a scientific journal, the data will be made public as soon as the manuscript  End point: disappearance/reduction of symptoms will be published. evaluated as difference in post/pre – VAS – Gastrointestinal and cutaneous symptoms – Oral challenge with Nickel – Drug consumption Di Gioacchino Di Gioacchino 6
  • 7. Conclusions  SNAS has a definite clinical pattern and is characterized by Thankyou for your attention specific immunologic features respect to Ni-ACD  Oral administration of Ni induces immunological changes (essentially reduction of Ni-induced inflammatory cytokine and increase in Ni induced regulatory cytokines) and clinical improvement. m.digioacchino@unich.it Di Gioacchino 7